Patents Assigned to Antonis
  • Publication number: 20220087981
    Abstract: The present invention relates to active agents or compounds as well as pharmaceutical compositions comprising said compounds, which are capable of reducing or inhibiting or blocking the enzymatic activity of the glutaminyl-peptide cyclotransferase (QPCT) protein, the glutaminyl-peptide cyclotransferase-like protein (QPCTL) protein, or combinations thereof or are capable of reducing or inhibiting the expression of QPCT gene, the QPCTL gene, or combinations thereof. Also provided are methods for screening or selecting for said compounds. The present invention further relates to a pharmaceutical composition comprising a first active agent for use in a method of treating a condition in a subject that would benefit from reducing the signaling or the binding between SIRP? and CD47 in the subject (e.g. cancer), wherein the method of treating comprises reducing expression or enzymatic activity of QPCTL, QPCT, or combinations thereof in the cell with CD47 on the surface.
    Type: Application
    Filed: April 23, 2021
    Publication date: March 24, 2022
    Applicants: Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, Academisch Ziekenhuis Leiden H.O.D. N. LUMC
    Inventors: Matthijs Raaben, Ferenc Alexander Scheeren, Meike Emma Willemijn Logtenberg, Thijn Reinout Brummelkamp, Antonius Nicolaas Maria Schumacher, Jeannette Henrica Wilhelmina Leusen
  • Patent number: 11162072
    Abstract: The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: November 2, 2021
    Assignees: BIONTECH US INC., Stichting Het Nederlands Kanker Instituut—Antoni Van Leeuwenhoek Ziekenhuis
    Inventors: Marit M. Van Buuren, Divya Reddy Lenkala, Joost Huibert Van Den Berg, Jessica Kohler, Matthew Goldstein, Ed Fritsch, Renate De Boer, Ton Schumacher, Noor Bakker
  • Publication number: 20210293820
    Abstract: Method of activating dysfunctional T cells, determining responsiveness of a subject having a tumor to an immune checkpoint inhibition are provided. Also provided is an agent capable of inhibiting a target gene or expression product thereof for use in treating a subject having a tumor. Additionally or alternatively provided is an immune checkpoint inhibitor and an agent capable of inhibiting a target gene or expression product thereof for use in treating a subject having a tumor.
    Type: Application
    Filed: May 31, 2021
    Publication date: September 23, 2021
    Applicants: Yeda Research and Development Co. Ltd., Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis
    Inventors: Ido AMIT, Hanjie LI, Amos TANAY, Ido YOFE, Yaniv EYAL-LUBLING, Antonius Nicolaas Maria SCHUMACHER, Anne Magdalena VAN DER LEUN
  • Publication number: 20210269505
    Abstract: The present invention relates to TWEAK-receptor agonists for use in the treatment of a cancer, wherein the TWEAK-receptor agonist is combined with immunotherapy of the cancer. The TWEAK-receptor agonist preferably is a multivalent ligand that causes clustering of TWEAK-receptors at the cell surface. A suitable TWEAK-receptor agonist is an agonistic anti-Fn14 antibody. The TWEAK-receptor agonist and immunotherapy be can further be combined with a SMAC mimetic in the treatment of cancer. The TWEAK-receptor agonist is useful, optionally in combination with a SMAC mimetic, to prevent resistance of a cancer to immunotherapy and/or to treat a cancer comprising tumor cells that are resistant to immunotherapy.
    Type: Application
    Filed: June 28, 2019
    Publication date: September 2, 2021
    Applicant: Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
    Inventors: Daniel Simon Peeper, Thomas Kuilman, David Willem Vredevoogd
  • Publication number: 20210045721
    Abstract: A surgical instrument is disclosed to remove tissue, in particular unhealthy tissue or tissue containing cancer cells, from a body and to analyse the removed tissue. A tissue removal device is arranged at a distal end of the surgical instrument, wherein the distal part of the surgical instrument comprises a movable part, for example a bendable part, to adjust a position and/or orientation of the tissue removal device with respect to a proximal end of the surgical instrument, wherein movement of the movable part can be controlled by an operator. A discharge channel is connected to the tissue removal device for discharge of removed tissue. A tissue analysis device comprises an analysis sensor to analyse non-removed tissue in front of the tissue removal device, wherein the tissue analysis device is configured to provide a sensor signal representative for an analysed characteristic of the tissue.
    Type: Application
    Filed: January 24, 2019
    Publication date: February 18, 2021
    Applicant: Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
    Inventors: Theodoor Jacques Marie Ruers, Henricus Josephus Cornelus Maria Sterenborg, Wouter Johannes Heerink
  • Patent number: 10864179
    Abstract: The current invention relates to treatment of drug resistant melanoma with histone deacetylase inhibitors (HDACi). In particular the invention relates to BRAF and NRAS mutated melanoma and that have acquired resistance to MAPK pathway inhibitors, for example due to previous treatment with such MAPK pathway inhibitors. The invention discloses HDACi and/or MAPK pathway inhibitors for use in such treatment and treatment regimens using such inhibitors.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: December 15, 2020
    Assignee: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Liqin Wang, Rodrigo Leite De Oliveira, Rene Bernards
  • Publication number: 20200347572
    Abstract: De-trenching apparatus (100) for extracting a buried line, such as a cable or pipeline, is disclosed. The de-trenching apparatus comprises a channel (112) configured to receive a buried line to be extracted, the channel comprising a first flared opening (114) at a front end of the de-trenching apparatus and a second flared opening (115) at the rear end of the de-trenching apparatus, the first and second flared openings each having a curved surface (111) configured to support the line during extraction, and material removal means for removing material from around the buried line ahead of the de-trenching apparatus.
    Type: Application
    Filed: October 25, 2018
    Publication date: November 5, 2020
    Applicant: Antony Zymelka c/o Zytech LTD
    Inventor: Antony Zymelka
  • Patent number: 10753862
    Abstract: In a method and apparatus, a property of an optically diffuse medium including a first optical absorber having a first concentration and a second optical absorber having a second concentration is determined. A surface area of the medium is imaged at multiple wavelengths around an isosbestic wavelength of the first absorber and the second absorber. A reflectance spectrum of the medium at the surface area at the multiple wavelengths is determined. A derivative of the determined reflectance spectrum around the isosbestic wavelength is determined. From the derivative, a concentration ratio of the first concentration and the second concentration is estimated.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: August 25, 2020
    Assignee: Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis
    Inventors: Theodoor Jacques Marie Ruers, Esther Kho, Henricus Josephus Cornelus Maria Sterenborg
  • Patent number: 10690658
    Abstract: The invention provides improved screening methods for testing T cell recognition of T cell epitopes.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: June 23, 2020
    Assignees: AIMM THERAPEUTICS B.V., STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Carsten Linnemann, Laura Bies, Marit Martha van Buuren, Antonius Nicolaas Maria Schumacher, Hergen Spits, Remko Schotte
  • Patent number: 10398696
    Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibitors of MEK, EGFR and ERBB2 in the treatment of KRAS-mutant lung cancer, and KRAS-mutant colon cancer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: September 3, 2019
    Assignee: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Chong Sun, Rene Bernards
  • Patent number: 10351845
    Abstract: The present invention comprises generally applicable methods for identifying endogenous physiologically relevant genetic elements that affects a intracellular phenotype of interest. In the methods, non-living cells that have been subjected to a mutagenesis treatment are sorted based on phenotype and analyzed to identify the genetic element. By use of these methods, elements previously unknown to be involved in a phenotype can be identified, for example in relationship to health conditions, external stress or drug response, in particular in cancer.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: July 16, 2019
    Assignee: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Thijn Reinout Brummelkamp, Joppe Daniël Maria Nieuwenhuis, Lucas Tilmann Jae, Markus Brockmann, Vincent Arthur Blomen, Matthijs Raaben
  • Publication number: 20180374613
    Abstract: Electrical cables are disclosed, comprising a layer of a two dimensional material. In some embodiments, the cable is a subsea cable. In other embodiments, the cable may be an overhead power cable or a cable for forming electrical windings in a motor, generator or transformer. In some embodiments, the cable comprises a conductive core for carrying an electric current, and the layer of two dimensional material is disposed on the conductive core. In some embodiments, the subsea cable is a subsea power cable, umbilical cable or telecommunications cable. In some embodiments, the two dimensional material is configured to be superconducting or near-superconducting.
    Type: Application
    Filed: November 30, 2016
    Publication date: December 27, 2018
    Applicant: Antony Zymelka c/o Zytech LTD
    Inventor: Antony Zymelka
  • Publication number: 20180333210
    Abstract: In a method and system for providing visual information about a tumour location in human or animal body, an electromagnetic tumour sensor is provided in the tumour and tracked to determine its location in space, which is mapped to a tumour model. A surgical tool sensor is provided on a surgical tool, and tracked to determine its location in space, which is mapped to a surgical tool model. The body is scanned to obtain information about an anatomical structure. A reference sensor is provided on the body, and tracked to determine its location in space, which is mapped to the anatomical structure. A virtual image is displayed showing the tumour model, located with the at least one tumour sensor, in spatial relationship to the surgical tool model, located with the at least one surgical tool sensor, and the anatomical structure, located with the at least one reference sensor.
    Type: Application
    Filed: November 18, 2016
    Publication date: November 22, 2018
    Applicant: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Jasper Albertus NIJKAMP, Koert Frans Dirk KUHLMANN, Jan-Jakob SONKE, Theodoor Jacques Marie RUERS
  • Publication number: 20170327549
    Abstract: The present invention concerns compounds that are capable of covalently entrapping adenylating enzymes. The present invention is essentially based on the discovery that analogues of adenylating enzyme (AE) substrates, wherein a methylene group has been incorporated at the carbon atom in the ?-position relative to the carboxylate group involved in the adenylation, are capable of undergoing the adenylation reaction, thereby creating an activated methylene group in situ. The resulting ‘armed’ acyladenylate can interact with the enzyme resulting in covalent entrapment. Interestingly, the acyladenylate can alternatively be transferred to the next step in the enzyme cascade, following which the activated methylene group can interact with the next (active site cysteine containing) enzyme in the enzymatic cascade.
    Type: Application
    Filed: August 26, 2015
    Publication date: November 16, 2017
    Applicant: Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
    Inventors: Huib Ovaa, Farid El Oualid, Monique Mulder
  • Patent number: 9629851
    Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibitors of ROCK and proteins of the MAPK/ERK-pathway in the treatment of KRAS-, NRAS- or BRAF-mutated cancer, in particular in NRAS mutated melanoma.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: April 25, 2017
    Assignee: STITCHING HET NEDERLANDS KANKER INSTITUT—ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Daniel Simon Peeper, Marjon Antoinetta Smit, Celia Jill Vogel
  • Patent number: 9516901
    Abstract: A pair of complementary articles of clothing, such as socks, that can be detachably connected to each other. The detachable connection can be made by first and second complementary connecting elements, which are each fastened to the article of clothing by a carrier element, wherein one of the ends of each carrier element forms a gripping area without a connecting function, so that the connection between the first and the second connecting element can be detached by pulling on the gripping areas of the carrier elements.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: December 13, 2016
    Assignee: ST. ANTONI LLC
    Inventors: Dewi Schoenbeck, John Schoenbeck
  • Publication number: 20140296248
    Abstract: The instant application provides methods and related compositions pertaining to the identification of resistance to anticancer treatment in a patient. In a particular embodiment, the invention provides biomarkers for the identification of resistance to anticancer treatment in a lung cancer patient, wherein a reduced expression of a MEDIATOR and/or SW1/SNF complex gene in the lung cancer cells of the patient indicates that the lung cancer cells in the patient may be resistant to treatment with a receptor tyrosine kinase inhibitor, such as gefitinib and/or erlotinib. In some embodiments, the invention relates to methods and related compositions for predicting resistance to anticancer treatment by detecting the expression levels of one or more TGF-beta pathway nucleic acids and/or proteins.
    Type: Application
    Filed: April 4, 2012
    Publication date: October 2, 2014
    Applicant: Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis
    Inventors: Rene Bernards, Sidong Huang, Michael Holzel
  • Publication number: 20140287931
    Abstract: The instant application provides methods and related compositions pertaining to the identification of resistance to anticancer treatment in. a patient. In a particular embodiment, the invention provides biomarkers for the identification of resistance to anticancer treatment in a breast cancer patient, wherein a reduced expression of a MEDIATOR and/or SWI/SNF complex gene in the breast cancer cells of the patient indicates that the breast cancer cells in the patient may be successfully treated with a PI3K and/or mTOR inhibitor.
    Type: Application
    Filed: April 4, 2012
    Publication date: September 25, 2014
    Applicant: Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis
    Inventors: Rene Bernards, Sidong Huang, Michael Holzel, Katrien Berns
  • Publication number: 20140220291
    Abstract: A pair of complementary articles of clothing, such as socks, that can be detachably connected to each other. The detachable connection can be made by first and second complementary connecting elements, which are each fastened to the article of clothing by a carrier element, wherein one of the ends of each carrier element forms a gripping area without a connecting function, so that the connection between the first and the second connecting element can be detached by pulling on the gripping areas of the carrier elements.
    Type: Application
    Filed: February 10, 2014
    Publication date: August 7, 2014
    Applicant: ST. ANTONI LLC
    Inventors: Dewi Schoenbeck, John Schoenbeck
  • Patent number: D773797
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: December 13, 2016
    Assignee: ST. ANTONI LLC
    Inventors: Dewi Schoenbeck, John Schoenbeck